Biochemical Dysfunction Clinical Trial
Official title:
Concordance of Capillary Blood Biological Samples Analyzed in Delocalized Biology With Conventional Venous Biological Blood Samples Analyzed at the Biology Laboratory
The main objectives are to evaluate the concordance between the results of natremia, kalaemia and blood sugar levels obtained 1) by capillary puncture, analysed on a delocalized resuscitation machine GEM 4000 (Werfen) and 2) by venous sampling, analysed on the machine of the standard biology laboratory Gen. 2 COBAS (Roche).
The completion of a biological test suits a succession of codified steps: - Medical prescription - The pre-analytic phase (preparation of the material, completion of the sample, transport of the sample and preparation of it) - The analytical phase - The post-analytic phase (validation of the result obtained and the dissemination of it to the prescriber, usually the clinician, who is then able to make a medical decision) This succession of steps involves, as part of a classical journey, many stakeholders (doctors, nurses, couriers, laboratory technicians, medical biologists) in different places. Outsourced biology (care test point, POCT) refers to the analysis of biological samples outside the central laboratory. The sample is most often carried out, transported and analyzed by the same person on a machine near the patient or in the service and therefore in the absence of direct control of a specialized laboratory technician or a medical biologist, who remains however responsible for good practice, maintenance of the device and validity of the results. The completion of biological examinations is regulated by differents Articles. The outsourced biology (ADBD) sampling analysis can be carried out in the hospital, in most departments, and also outside the hospital (pharmacies, city offices or even in the patient's own home). On portable devices, usually highly specialized, and these fixed allowing a greater diversity of tests. Its development is booming with annual growth estimated in 2006 at 15.5% in the United States. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05791916 -
Novel Biomarkers in Patients With Acute Myocardial Infarction
|
||
| Recruiting |
NCT05573997 -
Novel Echocardiographic Biomarkers Assessing the Myocardial Work in Heart Failure
|